Clinical trial
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative…
NCT00425854 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00425854 |
|---|---|
| Title | An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer |
| Official title | An Open Label Phase II Trial to Assess the Efficacy and Safety of a Once Daily Oral Dose of 50 mg BIBW 2992 in Two Cohorts of Patients With HER2-negative Metastatic Breast Cancer After Failure of no More Than Two Chemotherapy Regimen |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | BIBW 2992 |
| Enrollment | 50 |
| Start date | Nov 1, 2006 |
| Primary completion | May 1, 2009 |
| First posted | Jan 23, 2007 |
| Last update posted | Dec 31, 2013 |
| Countries | Belgium, Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: